Close

Gilead (GILD), Merck (MRK) Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Go back to Gilead (GILD), Merck (MRK) Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Gilead Sciences (GILD), Merck (MRK) Join Forces on Long-Acting HIV Therapy - WSJ

March 15, 2021 6:20 AM EDT

Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) are joining forces to develop a long-acting HIV therapy, according to the Wall Street Journal.

... More